

SCIRUS -   ☐ Pop-up Blocker OFF ☐ Highlight

- [About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Search Tips](#)
[Contact Us](#)

## Basic Search

[Advanced Search](#) [Search Preferences](#)

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase

Searched for:: :All of the words:catheter AND myocardium AND cells AND angiogenic AND factors

Found:: :405 total | [54 journal results](#) | [173 preferred web results](#) | [178 other web results](#)

Sort by:: :[relevance](#) | [date](#)

- ☐ 1. [Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic ...](#) [72K]

**Hiroshi Kamihata \* , / Hiroaki Matsubara , / Takashi Nishiue \* , / Soichiro Fujiyama \* , / Katsuya Amano \* , , Oct 2005**

...saline-implanted **myocardium**, the ischemic...Conclusions **Catheter**-based implantation...ischemic **myocardium** by its ability...mainly supply **angiogenic factors** and cytokines...marrow stem **cells** ischemic **myocardium** Introduction...surgical or **catheter**-based delivery...

[more hits from](#) [http://ahavj.ahajournals.org/cgi/content/full/atvbaha;...]

[similar results](#)

Dis  
cat  
"ar

You  
cat  
AN  
fac  
We  
qu  
anc  
ess

- ☐ 2. [Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic ...](#) [102K]

**Hiroshi Kamihata \* / Hiroaki Matsubara / Takashi Nishiue \* / Soichiro Fujiyama \* / Katsuya Amano \* , Apr 2005**

...saline-implanted **myocardium**, the ischemic...Conclusions **Catheter**-based implantation...ischemic **myocardium** by its ability...mainly supply **angiogenic factors** and cytokines...marrow stem **cells** ischemic **myocardium** Introduction...surgical or **catheter**-based delivery...

[more hits from](#) [http://atvb.ahajournals.org/cgi/content/full/22/11/180...]

[similar results](#)

Re  
us  
fo  
cel  
cel  
en  
ge  
inf

- ☐ 3. [INTRAMYOCARDIAL INJECTION OF AUTOLOGOUS BONE MARROW](#)

**EPSTEIN, Stephen / FUCHS, Shmuel / KORNOWSKI, Ran / LEON, Martine, B. / CARPENTER, Kenneth, W. / MYOCARDIAL THERAPEUTICS, INC., PATENT COOPERATION TREATY APPLICATION, Dec 2003**

...bone marrow **cells**. More specifically...bone marrow **cells** to enhance...ischemic **myocardium** by vascular...for kans-**catheter** delivery of **angiogenic factors** have employed...of these **cells** to secrete many **angiogenic factors** in a time-appropriate...ischemic **myocardium**. &lsqb;00071...

**Full text available at patent office. For more in-depth searching go to**  LexisNexis





[similar results](#)

inf  
isc  
me  
my  
my  
pro  
ski  
the  
the  
tra

- ☐ 4. [Unchain my heart: the scientific foundations of cardiac repair -- Dimmeler et al. 115 \(3\): 572 -- Journal of Clinical ...](#) [150K]

**Stefanie Dimmeler / Andreas M. Zeiher / Michael D. Schneider** , Mar 2005  
...multipotent **cells** from other sources...progenitor or stem **cells** discovered in the adult **myocardium** see text for...over-the-wire balloon **catheters**), intramuscular...of progenitor **cells** into scar tissue...hibernating **myocardium** by **catheter**-based needle...  
[more hits from \[http://www.jci.org/cgi/content/full/115/3/572\]](http://www.jci.org/cgi/content/full/115/3/572)  
[similar results](#)

ve  
Or  
AI  
f

- ☐ 5. INTRAMYOCARDIAL INJECTION OF AUTOLOGOUS BONE MARROW  
**KORNOWSKI, Ran / FUCHS, Shmuel / EPSTEIN, Stephen, E. / LEON, Martin, B. / KORNOWSKI, Ran, PATENT COOPERATION TREATY APPLICATION**, Oct 2000  
...ischemic **myocardium** by vascular...for trans- **catheter** delivery of **angiogenic factors** have employed...regions of the **myocardium** rather than...production of **angiogenic factors** is ex-vivo...bone marrow **cells** to hypoxia...ischemic **myocardium**, or directly...  
**Full text available at patent office. For more in-depth searching go to**  LexisNexis  
[similar results](#)
- ☐ 6. MUSCLE CELLS AND THEIR USE IN CARDIAC REPAIR  
**EDGE, Albert / DINSMORE, Jonathan / DIACRIN, INC., PATENT COOPERATION TREATY APPLICATION**, Oct 2003  
...of the act of transplanting the **cells**, as a result of the secretion of **angiogenic factors** from the muscle **cells**, and/or as a result of the secretion of endogenous **angiogenic factors** from the heart tissue. 15 As used...  
**Full text available at patent office. For more in-depth searching go to**  LexisNexis  
[similar results](#)
- ☐ 7. INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM FOR ANGIOGENESIS  
**EPSTEIN, Stephen / FUCHS, Shmuel / KORNOWSKI, Ran / LEON, Martin, B. / CARPENTER, Kenneth, W. / MYOCARDIAL THERAPEUTICS, INC., PATENT COOPERATION TREATY APPLICATION**, Jan 2005  
...these **cells** while the **cells** are grown in culture...natural ability of these **cells** to secrete many **angiogenic factors** in a time-appropriate...development in ischemic **myocardium**.  
**Full text available at patent office. For more in-depth searching go to**  LexisNexis  
[similar results](#)
- ☐ 8. Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in...  
**Tang, Y.L. / Zhao, Q. / Qin, X. / Shen, L. / Cheng, L. / Ge, J. / Phillips, M.I., The Annals of Thoracic Surgery**, Jul 2005  
...with mesenchymal stem **cells** induced greater basic...engrafted mesenchymal stem **cells** (MSCs) stimulate angiogenesis...implantation. Results The **angiogenic factors** basic fibroblast growth...protein Bax in ischemic **myocardium**. Similarly, capillary...action of the engrafted **cells**, increasing angiogenesis...  
**Full text article available from**  ScienceDirect  
[similar results](#)
- ☐ 9. Therapeutic angiogenesis and vasculogenesis for tissue regeneration -- Madeddu 90 (3): 315 -- Experimental Physiology [133K]  
**Paolo Madeddu / Porto Conte** , May 2005  
...vascular progenitor **cells**. These supplements...damaged tissues. **Angiogenic factors** are generally...called direct **angiogenic factors**. In addition...direct factors from **cells** recruited into...that of other **angiogenic factors** Nicosia et al...resident cardiac stem **cells**, resulting in...  
[<http://ep.physoc.org/cgi/content/full/90/3/315>]  
[similar results](#)
- ☐ 10. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with...  
**Fuchs, S. / Baffour, R. / Zhou, Y.F. / Shou, M. / Pierre, A. / Tio, F.O. /**

**Weissman, N.J. / (...) / Kornowski, R., *Journal of the American College of Cardiology*, May 2001**

...ischemic porcine **myocardium**. We also...marrow (BM) **cells** secrete vascular...multiple **angiogenic factors**, we thought...Bone marrow **cells** secrete **angiogenic factors** that induce...ischemic **myocardium**. ABM autologous...ability certain **cells** and tissues...to secrete **angiogenic factors** in a time-appropriate...ischemic porcine **myocardium** enhances...

**Full text article available from**  **SCIENCE DIRECT**

[similar results](#)

- ☐ **11. Implantation of Bone Marrow Mononuclear Cells Into Ischemic Myocardium Enhances Collateral Perfusion and Regional Function via ...** [153K]

Dec 2004

...euthanized by removal of the **myocardium**. BM **cells** 25 mL) were aspirated...Implantation Into Ischemic **Myocardium** Immediately after aspiration...CMECs (n=5) (total 10 8 **cells**, 25 sites x 0.02 mL...performed. A fluid-filled **catheter** was introduced into...

[more hits from](http://www.circ.ahajournals.org/cgi/content/full/104/9...) [http://www.circ.ahajournals.org/cgi/content/full/104/9...]

[similar results](#)

- ☐ **12. Angiogenesis by Implantation of Peripheral Blood Mononuclear Cells and Platelets Into Ischemic Limbs -- Iba et al. 106 (15): ...** [109K]

**Iba, O / Osamu Iba / MD Hiroaki / Matsubara, MD / PhD Yoshihisa Nozawa, Oct 2004**

...mononuclear **cells** (PBMNCs), platelets...contain various **angiogenic factors** and cytokines...mononuclear **cells** (BM-MNCs) contain...EPCs but also **angiogenic factors** and cytokines...introduce a **catheter** into the abdominal...endothelial **cells** (HUVECs, Cascade...to neutralize **angiogenic factors** included in...

[more hits from](http://circ.ahajournals.org/cgi/content/full/106/15/20...) [http://circ.ahajournals.org/cgi/content/full/106/15/20...]

[similar results](#)

- ☐ **13. Cells, scaffolds, and molecules for myocardial tissue engineering**

**Leor, J. / Amsalem, Y. / Cohen, S., *Pharmacology and Therapeutics*, Feb 2005**

...stem/progenitor **cells** creating granulation...the infarcted **myocardium**. The granulation...the injured **myocardium** by transplantation of healthy **cells**. Several cell...chronically infarcted **myocardium** remains uncertain...autologous adult stem **cells** is particularly...

**Full text article available from**  **SCIENCE DIRECT**

[similar results](#)

- ☐ **14. Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic ...** [31K]

Oct 2004

...region and to inject **cells**. PB-MNCs and BM-MNCs...saline-implanted **myocardium**, the ischemic area...Conclusions **Catheter**-based implantation...hibernating ischemic **myocardium** by its ability to mainly supply **angiogenic factors** and cytokines...marrow stem **cells** ischemic **myocardium**...

[more hits from](http://intl-atvb.ahajournals.org/cgi/content/short/22/...) [http://intl-atvb.ahajournals.org/cgi/content/short/22/...]

[similar results](#)

- ☐ **15. CATHETER ASSEMBLY FOR TREATING ISCHEMIC TISSUE**

**AHN, Samuel, S. / BIOHEART, INC., PATENT COOPERATION TREATY APPLICATION, Jun 2002**

...channels within the **myocardium** for providing oxygenated...blood to myocardial **cells** without requiring...carried into the **myocardium** through the heart...the position of a **catheter** once it is inside...suspension (i.e., 15 **cells** suspended in a...therapeutic compound or **angiogenic factors** such as solutions...


**Full text available at patent office. For more in-depth searching go to**  **LexisNexis**

[similar results](#)

16. CATHETER ASSEMBLY FOR TREATING ISCHEMIC TISSUE

**LEONHARDT, Howard, J. / BIOHEART, INC., PATENT COOPERATION TREATY APPLICATION**, Jun 2002


...the diseased **myocardium**. The stent is carried into the **myocardium** through the...position of a **catheter** once it is inside...suspension (i.e., 15 **cells** suspended in...combinations of **cells** mixed in a nutrient...compound or **angiogenic factors** such as solutions...the use of a **catheter**- based deployment...

**Full text available at patent office. For more in-depth searching go to**  **LexisNexis**  
[similar results](#)

17. CELLULAR TRANSPLANTATION FOR HEART REGENERATION

**LAW, Peter, K. / LAW, Peter, K., PATENT COOPERATION TREATY APPLICATION**, Oct 2003


...of the recruited stem **cells** differentiate to become...inability to add new **cells** of the right amount...revascularization using laser, **angiogenic factors** and genes, the damaged **myocardium** needs additional live **cells** to deposit contractile...

**Full text available at patent office. For more in-depth searching go to**  **LexisNexis**  
[similar results](#)

18. SYSTEM FOR TREATING ISCHEMIA

**CAFFERATA, Robert, L. / C.R. Bard Inc., EUROPEAN PATENT**, Jul 2001


...of functioning **myocardium** after frank infarction...replenishing of viable **cells** that can assume...balloon dilation **catheter** a drug delivery...to infarcted **myocardium** where these therapeutic...angiogenesis and **cells** adapted for implantation in the **myocardium**. The techniques...herein include **catheter** systems for delivery...

**Full text available at patent office. For more in-depth searching go to**  **LexisNexis**  
[similar results](#)

19. DEVICES, SYSTEMS AND METHODS FOR ACUTE OR CHRONIC DELIVERY OF SUBSTANCES OR APPARATUS TO EXTRAVASCULAR TREATMENT SITES

**MAKOWER, Joshua / LAMSON, Theodore, C. / FLAHERTY, J., Christopher / REGGIE, John, A. / CHANG, John, Y. / CANTANESE, III., Joseph / THOLFSEN, David, R. / TRANSVASCULAR, INC., PATENT COOPERATION TREATY APPLICATION**, Jul 2002

...has also included **catheter** devices that may...or needle from a **catheter** located within...Examples of these 25 **catheter** devices useable...genetically modified **cells**, naked DNA), biological factors (e.g., **angiogenic factors**, nerve growth factors...ischemic areas of **myocardium** may result in...

**Full text available at patent office. For more in-depth searching go to**  **LexisNexis**  
[similar results](#)

20. Abstracts

**Waksman, R., Cardiovascular Radiation Medicine**, Oct 2004

...Abstract 105 Adult stem **cells** and **angiogenic factors** for myogenesis and...bone marrow stromal **cells** and **angiogenic factors** to induce myogenesis...Including the stem **cells** expressing **angiogenic factors** did not further improve...

**Full text article available from**  **SCIENCE DIRECT**  
[similar results](#)

**fast** 

**Results Pages:** [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)  
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by **FAST** © Elsevier 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/Capplus-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of Capplus documents for use in third-party analysis and  
visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/Capplus - Expanded coverage of German academic research  
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental  
spectral property data  
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available  
  
NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:48:19 ON 11 DEC 2005

=> file caplus uspatful japio epfull medline biosis embase scisearch  
COST IN U.S. DOLLARS                      SINCE FILE              TOTAL  
                                                                         ENTRY              SESSION  
FULL ESTIMATED COST                      0.21              0.21

FILE 'CAPLUS' ENTERED AT 17:48:45 ON 11 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:48:45 ON 11 DEC 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:48:45 ON 11 DEC 2005  
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 17:48:45 ON 11 DEC 2005  
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 17:48:45 ON 11 DEC 2005

FILE 'BIOSIS' ENTERED AT 17:48:45 ON 11 DEC 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:48:45 ON 11 DEC 2005  
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:48:45 ON 11 DEC 2005  
Copyright (c) 2005 The Thomson Corporation

=> s (myocard? or cardiac? or heart) and (contract? or beat or heartbeat)  
L1 303305 (MYOCARD? OR CARDIAC? OR HEART) AND (CONTRACT? OR BEAT OR HEARTB  
EAT)

=> s l1 and catheter?  
L2 24787 L1 AND CATHETER?

=> s l2 and angiogenic?  
L3 1331 L2 AND ANGIOGENIC?

=> s l3 and cell?  
L4 1290 L3 AND CELL?

=> s l4 and regenerat?  
L5 752 L4 AND REGENERAT?

=> s l5 and cardiomyocyte#  
L6 343 L5 AND CARDIOMYOCYTE#

=> s l6 and fibroblast#  
L7 341 L6 AND FIBROBLAST#

=> s l7 and (bone marrow stromal)  
L8 171 L7 AND (BONE MARROW STROMAL)

=> s l8 and reperfusion?  
L9 163 L8 AND REPERFUSION?

=> s l9 and (damag? or infarct?)  
L10 163 L9 AND (DAMAG? OR INFARCT?)

=> s l10 and implant?  
L11 163 L10 AND IMPLANT?

=> s L11 and pellet  
L12 155 L11 AND PELLET

=> s l12 and ((timed release) or (controlled release))  
L13 149 L12 AND ((TIMED RELEASE) OR (CONTROLLED RELEASE))

=> s l13 and guid?  
L14 149 L13 AND GUID?

=> s l14 and (distal)  
L15 149 L14 AND (DISTAL)

=> s l15 and sequential?  
L16 149 L15 AND SEQUENTIAL?

=> s l16 and contract?  
L17 149 L16 AND CONTRACT?

=> s l17 and ischem?  
L18 149 L17 AND ISCHEM?

=> s l18 and (treat? or therap?)  
L19 149 L18 AND (TREAT? OR THERAP?)

=> s l19 and (contractile function)  
L20 0 L19 AND (CONTRACTILE FUNCTION)

=> s l19 and (contractile muscle)  
L21 0 L19 AND (CONTRACTILE MUSCLE)

=> s l21 and (distal end)  
L22 0 L21 AND (DISTAL END)

=> d his

(FILE 'HOME' ENTERED AT 17:48:19 ON 11 DEC 2005)

FILE 'CAPLUS, USPATFULL, JAPIO, EPFULL, MEDLINE, BIOSIS, EMBASE,  
SCISEARCH' ENTERED AT 17:48:45 ON 11 DEC 2005

L1 303305 S (MYOCARD? OR CARDIAC? OR HEART) AND (CONTRACT? OR BEAT OR HEA  
L2 24787 S L1 AND CATHETER?  
L3 1331 S L2 AND ANGIOGENIC?  
L4 1290 S L3 AND CELL?  
L5 752 S L4 AND REGENERAT?  
L6 343 S L5 AND CARDIOMYOCYTE#  
L7 341 S L6 AND FIBROBLAST#  
L8 171 S L7 AND (BONE MARROW STROMAL)  
L9 163 S L8 AND REPERFUSION?  
L10 163 S L9 AND (DAMAG? OR INFARCT?)  
L11 163 S L10 AND IMPLANT?  
L12 155 S L11 AND PELLET  
L13 149 S L12 AND ((TIMED RELEASE) OR (CONTROLLED RELEASE))  
L14 149 S L13 AND GUID?  
L15 149 S L14 AND (DISTAL)  
L16 149 S L15 AND SEQUENTIAL?  
L17 149 S L16 AND CONTRACT?  
L18 149 S L17 AND ISCHEM?  
L19 149 S L18 AND (TREAT? OR THERAP?)  
L20 0 S L19 AND (CONTRACTILE FUNCTION)  
L21 0 S L19 AND (CONTRACTILE MUSCLE)  
L22 0 S L21 AND (DISTAL END)

=> s l19 and myocardium  
L23 8 L19 AND MYOCARDIUM

=> d l23 1-8 ibib abs

L23 ANSWER 1 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2005:247591 USPATFULL  
TITLE: 26 human secreted proteins  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Komatsoulis, George A., Silver Spring, MD, UNITED STATES  
Choi, Gil H., Rockville, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Baker, Kevin P., Darnestown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Brookeville, MD, UNITED STATES  
Fiscella, Michele, Bethesda, MD, UNITED STATES  
Moore, Paul A., North Bethesda, MD, UNITED STATES  
Wei, Ping, Agoura Hills, CA, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005214786	A1	20050929
APPLICATION INFO.:	US 2004-921235	A1	20040819 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2003-US4819, filed on 20 Feb 2003, PENDING Continuation-in-part of Ser. No. WO 2003-US4818, filed on 20 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358554P	20020222 (60)
	US 2002-358714P	20020225 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25499	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing and **treating** diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2005:202642 USPATFULL  
TITLE: Human secreted proteins  
INVENTOR(S): Rosen, Craig A, Laytonsville, MD, UNITED STATES  
Ruben, Steven M, Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005176061	A1	20050811
APPLICATION INFO.:	US 2003-472953	A1	20020326 (10)
	WO 2002-US9105		20020326

NUMBER	DATE
--------	------



-----

PRIORITY INFORMATION: US 2003-60278650 20010327  
 US 2003-60950082 20010912  
 US 2003-60950083 20010912

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT.,  
 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

NUMBER OF CLAIMS: 32  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 40795

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diabetes mellitus and/or conditions related to diabetes. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:321019 USPATFULL  
 TITLE: 20 human secreted proteins  
 INVENTOR(S): Ruben, Steven M., Brookeville, MD, UNITED STATES  
 Bell, Adam, Germantown, MD, UNITED STATES  
 Birse, Charles E., North Potomac, MD, UNITED STATES  
 Komatsoulis, George A., Silver Spring, MD, UNITED STATES  
 Choi, Gil H., Rockville, MD, UNITED STATES  
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Baker, Kevin P., Darnestown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004253672	A1	20041216
APPLICATION INFO.:	US 2003-726699	A1	20031204 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-US17699, filed on 5 Jun 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295869P	20010606 (60)
	US 2001-304121P	20010711 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25432	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted

proteins. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing and **treating** diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:12971 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, **treating**, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host **cells**, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:12968 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)

US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)

US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 32038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:7345 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed		

on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, **treating**, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host **cells**, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER:	2003:160075	USPATFULL
TITLE:	Colon and colon cancer associated polynucleotides and polypeptides	
INVENTOR(S):	Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steve C., Rockville, MD, UNITED STATES Birse, Charles E., North Potomac, MD, UNITED STATES Rosen, Craig A., Laytonsville, MD, UNITED STATES	
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109690	A1	20030612
APPLICATION INFO.:	US 2002-106698	A1	20020327 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US26524, filed on 28 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157137P	19990929 (60)
	US 1999-163280P	19991103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

LINE COUNT: 17981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host **cells**, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the colon, including colon cancer, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 8 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:266261 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147140	A1	20021010
APPLICATION INFO.:	US 2001-764877	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)

US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 33677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host **cells**, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and **therapeutic** methods useful for diagnosing, **treating**, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and **therapeutic** methods for **treating** such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of CAPLUS documents for use in third-party analysis and  
visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research  
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental  
spectral property data  
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available  
  
NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 19:15:54 ON 11 DEC 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 19:15:58 ON 11 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Dec 9, 2005 (20051209/UP).

=> FIL HOME		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 19:16:03 ON 11 DEC 2005

=> file caplus uspatul japio eptfull medline biosis embase scisearch  
'USPATUL' IS NOT A VALID FILE NAME  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files  
that are available. If you have requested multiple files, you can  
specify a corrected file name or you can enter "IGNORE" to continue  
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):uspatfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'CAPLUS' ENTERED AT 19:16:32 ON 11 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 19:16:32 ON 11 DEC 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 19:16:32 ON 11 DEC 2005  
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 19:16:32 ON 11 DEC 2005  
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 19:16:32 ON 11 DEC 2005

FILE 'BIOSIS' ENTERED AT 19:16:32 ON 11 DEC 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 19:16:32 ON 11 DEC 2005  
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 19:16:32 ON 11 DEC 2005  
Copyright (c) 2005 The Thomson Corporation

=> s implant? and myocard?  
L1 35193 IMPLANT? AND MYOCARD?

=> s l1 and ischem?  
L2 13027 L1 AND ISCHEM?

=> s l2 and ((bone marrow) or fibroblast#)  
2 FILES SEARCHED...  
L3 4737 L2 AND ((BONE MARROW) OR FIBROBLAST#)

=> s l3 and catheter

L4 1938 L3 AND CATHETER

=> s l4 and (angiogenic factor#)  
L5 685 L4 AND (ANGIOGENIC FACTOR#)

=> s l5 and (contractile?)  
L6 95 L5 AND (CONTRACTILE?)

=> s l6 and direct?  
L7 95 L6 AND DIRECT?

=> s l7 and angiogenesis  
L8 93 L7 AND ANGIOGENESIS

=> s l8 and regenerat?  
L9 54 L8 AND REGENERAT?

=> d l9 1-54 ibib ab

L9 ANSWER 1 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:312080 USPATFULL  
TITLE: Local delivery of growth factors for stem cell  
transplantation  
INVENTOR(S): Litvack, Frank, Los Angeles, CA, UNITED STATES  
PATENT ASSIGNEE(S): Conor Medsystems, Inc., Menlo Park, CA, UNITED STATES  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005271697	A1	20051208
APPLICATION INFO.:	US 2005-148002	A1	20050607 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-578122P	20040607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CINDY A. LYNCH, CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK, CA, 94025, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	872	

AB A method and apparatus for local delivery of growth factors which enhances stem cell **regeneration** of the heart is disclosed. In one example, a stent containing growth factor within openings in the stent delivers the growth factor into a coronary artery to improve effectiveness of the stem cell transplantation therapy. The stent may also be used to transplant stem cells and deliver other bioactive factors.

L9 ANSWER 2 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:312014 USPATFULL  
TITLE: Material compositions and related systems and methods  
for treating cardiac conditions  
INVENTOR(S): Lee, Randall J., Hillsborough, CA, UNITED STATES  
Christman, Karen, Carpinteria, CA, UNITED STATES  
Sievers, Richard, Petaluma, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005271631	A1	20051208
APPLICATION INFO.:	US 2005-129046	A1	20050512 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2003-US23162, filed on 25  
Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-429914P	20021129 (60)
	US 2002-431287P	20021206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN P. O'BANION, O'BANION & RITCHEY LLP, 400 CAPITOL MALL SUITE 1550, SACRAMENTO, CA, 95814, US	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	2997	

AB A medical condition associated with a cardiac structure is treated by injecting an injectable polymer agent into the cardiac structure such that a therapeutic mechanical scaffolding is formed within the cardiac structure itself. In particular, the injectable scaffolding agent is a fibrin glue agent and is injected into regions of damaged **myocardium** such as **ischemic** tissue or infarct. LV wall dysfunction may also be treated by injecting the scaffolding agent into the LV wall. Cell therapy may be combined with the injection of fibrin glue or other injectable polymer scaffold agent. The polymeric forms of the agent may be injectable as precursor materials that polymerize as a scaffold in-situ within the cardiac structure. In other modes, polymer agents are injected in order to provide therapeutic **angiogenesis**, or to induce deposition of cells within the injected area, such as by providing the polymer with fragment E or RDG binding sites, respectively.

L9 ANSWER 3 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:286938 USPATFULL  
TITLE: Adipose stromal stem cells for tissue and vascular  
modification  
INVENTOR(S): March, Keith L., Carmel, IN, UNITED STATES  
Rehman, Jalees, Zionsville, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005250202	A1	20051110
APPLICATION INFO.:	US 2003-508223	A1	20030319 (10)
	WO 2003-US8582		20030319
			20050623 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-365498P	20020319 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307, US	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1431	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated adipose derived stromal cells and methods of use thereof.

L9 ANSWER 4 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:280441 USPATFULL  
TITLE: Cellular transplantation for heart **regeneration**

INVENTOR(S) : Law, Peter K., Ontario, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005244384	A1	20051103
APPLICATION INFO.:	US 2003-509940	A1	20030331 (10)
	WO 2003-US9505		20030331
			20050603 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-368563P	20020401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 1717 RHODE ISLAND AVE, NW, WASHINGTON, DC, 20036-3001, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1019	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. **Angiogenesis** factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated **catheter** delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.

L9 ANSWER 5 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:241559 USPATFULL  
TITLE: Devices and methods for interstitial injection of biologic agents into tissue  
INVENTOR(S) : Bonner, Matthew D., Plymouth, MN, UNITED STATES  
Rothstein, Paul T., Elk River, MN, UNITED STATES  
Hiniduma-Lokuge, Prasanga D., Minneapolis, MN, UNITED STATES  
Usher, Raymond W., Coon Rapids, MN, UNITED STATES  
Keogh, James R., Maplewood, MN, UNITED STATES  
Jahns, Scott Eric, Hudson, WI, UNITED STATES  
Chen, Victor T., Minneapolis, MN, UNITED STATES  
PATENT ASSIGNEE(S) : Medtronic, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209564	A1	20050922
APPLICATION INFO.:	US 2004-798	A1	20041130 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-341743, filed on 14 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2003-622147, filed on 17 Jul 2003, GRANTED, Pat. No. US 6918908 Continuation-in-part of Ser. No. US 2002-156315, filed on 28 May 2002, PENDING Continuation-in-part of Ser. No. US 2003-342932, filed on 15 Jan 2003, GRANTED, Pat. No. US 6837848 Continuation-in-part of Ser. No. US 2001-879294, filed on 12 Jun 2001, GRANTED, Pat. No. US 6447443		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-261343P	20010113 (60)
	US 2001-263739P	20010124 (60)
	US 2001-282029P	20010406 (60)
	US 2001-286952P	20010426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jeffrey J. Hohenshell, 7601 Northland Drive, Minneapolis, MN, 55428, US	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	56 Drawing Page(s)	
LINE COUNT:	3706	

AB Apparatus and methods for injecting biological agents into tissue. Devices are provided having elongate shafts and distal injection heads for driving needles into tissue and injecting medical agents into the tissue through the needles. A longitudinal force **directed** along the shaft can be translated to a needle driving force. Some devices provide controllably variable needle penetration depth. Devices include mechanical needle drivers utilizing four link pantographs, rack and pinions, and drive yokes for driving a first needle bearing body toward a second tissue contacting body. Other devices include inflatable members for driving and retracting needles. Still other devices include magnets for biasing the needles in extended and/or retracted positions. The invention includes minimally invasive methods for epicardially injecting cardiocyte precursor cells into infarct **myocardial** tissue.

L9 ANSWER 6 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:240526 USPATFULL  
 TITLE: Polynucleotide encoding a novel human G-protein coupled receptor variant of the relaxin receptor, HGPRBMY5v1, and variants thereof  
 INVENTOR(S): Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
 Feder, John N., Belle Mead, NJ, UNITED STATES  
 Mintier, Gabriel, Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2005208526	A1	20050922
APPLICATION INFO.:	US 2004-994987	A1	20041122 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2003-525021P	20031125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	15351	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention provides novel polynucleotides encoding HGPRBMY5v1 and HGPRBMY5v2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY5v1 and HGPRBMY5v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these

polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L9 ANSWER 7 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:236070 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6946134	B1	20050920
APPLICATION INFO.:	US 2001-833111		20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Carlson, Karen Cochrane  
ASSISTANT EXAMINER: Robinson, Hope A.  
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
NUMBER OF CLAIMS: 25  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 20 Drawing Page(s)  
LINE COUNT: 23429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L9 ANSWER 8 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:203680 USPATFULL  
TITLE: Medical device for delivering patches  
INVENTOR(S): Naimark, Wendy, Cambridge, MA, UNITED STATES  
Palasis, Maria, Wellesley, MA, UNITED STATES  
PATENT ASSIGNEE(S): Scimed Life Systems, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005177106	A1	20050811
APPLICATION INFO.:	US 2005-76552	A1	20050309 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-977758, filed on 15 Oct 2001, GRANTED, Pat. No. US 6893431		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	1400		

AB The present invention relates to a medical device and method for treating the body tissue of a patient. The present invention is also **directed** to a method of making the medical device and a method of using the medical device. More particularly, the invention relates to a medical device which is inserted into the body for delivery of therapeutic patches to the surface of a body lumen, organ or cavity. Specifically, the medical device has an umbrella-like or a basket-like expandable assembly; and a therapeutic patch. The expandable assembly is capable of changing from a retracted position to an expanded position. The expandable assembly can be self-expanding or non-self-expanding. In one embodiment, the medical device comprises an elongated member; an umbrella-like expandable assembly which has a plurality of wire elements; and a therapeutic patch. The therapeutic patch comprises a sheet having two opposing surfaces wherein one of the surface comprises an adhesive material and at least one biologically active material. The other opposing surface is disposed onto the plurality of wire elements of the umbrella-like expandable assembly. In another embodiment, the medical device comprises an elongated member, a basket-like expandable assembly having a plurality of wire elements; and a therapeutic patch. The therapeutic patch is disposed onto the plurality of wire elements of the basket-like expandable assembly.

L9 ANSWER 9 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:183014 USPATFULL

TITLE: Materials from **bone marrow** stromal cells for use in forming blood vessels and producing angiogenic and trophic factors

INVENTOR(S): Chopp, Michael, Southfield, MI, UNITED STATES  
Li, Yi, Canton, MI, UNITED STATES  
Chen, Xiaoguang, Madison Heights, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158397	A1	20050721
APPLICATION INFO.:	US 2003-502723	A1	20030114 (10)
	WO 2003-US1129		20030114

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-348955P	20020114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2270	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic for use in inducing **angiogenesis** and vasculogenesis, the therapeutic including **angiogenesis** and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of **angiogenesis** and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of **angiogenesis** and vasculogenesis inducing factors. **Angiogenesis** and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the **angiogenesis** and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for



neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.

L9 ANSWER 10 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:140271 USPATFULL  
TITLE: Cardiac disease treatment and device  
INVENTOR(S): Walsh, Robert G., Lakeville, MN, UNITED STATES  
Shapland, II, J. Edward, Vadnais Heights, MN, UNITED STATES  
Rohrbaugh, Donald G., Minnetonka, MN, UNITED STATES  
Palme, II, Donald F., Princeton, MN, UNITED STATES  
PATENT ASSIGNEE(S): Acorn Cardiovascular, Inc., St. Paul, MN, UNITED STATES  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6902522	B1	20050607
APPLICATION INFO.:	US 2000-591754		20000612 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lucchesi, Nicholas D.		
ASSISTANT EXAMINER:	Maiorino, Roz		
LEGAL REPRESENTATIVE:	Merchant & Gould P.C.		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1826		

AB A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A-V groove, the device including a jacket adapted to be secured to the heart, and a delivery source for the delivery of one or more therapeutic agents to the surface of the heart. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.

L9 ANSWER 11 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:43739 USPATFULL  
TITLE: 83 human secreted proteins  
INVENTOR(S): Ruben, Steven M., Brookeville, MD, UNITED STATES  
Feng, Ping, Germantown, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Moore, Paul A., North Bethesda, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Kyaw, Hla, Boonsboro, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Zeng, ZhiZhen, Lansdale, PA, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Fan, Ping, Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005037467	A1	20050217
APPLICATION INFO.:	US 2004-936773	A1	20040909 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-160162, filed on 4 Jun 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-820649, filed on 30 Mar 2001, PENDING Continuation of Ser. No. US 2000-666984, filed on 21 Sep 2000, ABANDONED Continuation of Ser. No. US 1999-236557, filed on 26 Jan 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US15949, filed on 29 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295558P	20010605 (60)
	US 1997-54209P	19970730 (60)
	US 1997-54211P	19970730 (60)
	US 1997-54212P	19970730 (60)
	US 1997-54213P	19970730 (60)
	US 1997-54214P	19970730 (60)
	US 1997-54215P	19970730 (60)
	US 1997-54217P	19970730 (60)
	US 1997-54218P	19970730 (60)
	US 1997-54234P	19970730 (60)
	US 1997-54236P	19970730 (60)
	US 1997-55968P	19970818 (60)
	US 1997-55969P	19970818 (60)
	US 1997-55972P	19970818 (60)
	US 1997-56534P	19970819 (60)
	US 1997-56543P	19970819 (60)
	US 1997-56554P	19970819 (60)
	US 1997-56561P	19970819 (60)
	US 1997-56727P	19970819 (60)
	US 1997-56729P	19970819 (60)
	US 1997-56730P	19970819 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT.,  
14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 24057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L9 ANSWER 12 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:38013 USPATFULL

TITLE: Novel polypeptides, their nucleic acids, and methods for their use in **angiogenesis** and vascularization

INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Goddard, Audrey, San Francisco, CA, UNITED STATES  
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Mehraban, Fuad, Trumbull, CT, UNITED STATES  
Genentech, Inc., South San Francisco, CA (U.S.  
corporation)  
Curagen Corporation, New Haven, CT (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032693	A1	20050210
APPLICATION INFO.:	US 2004-811080	A1	20040326 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-684458, filed on 5 Oct 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158587P	19991007 (60)
	US 1999-162611P	19991028 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9418	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention is **directed** to novel polypeptides critical for **angiogenesis** and vascularization, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Compositions and methods are disclosed for stimulating or inhibiting **angiogenesis** and/or neo- or cardio-vascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds; various cancers, and disorders of the vessels including atherosclerosis.

L9 ANSWER 13 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:10494 USPATFULL

TITLE: Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

INVENTOR(S): Fraser, John K., Los Angeles, CA, UNITED STATES  
Hedrick, Marc H., Encino, CA, UNITED STATES  
Zhu, Min, San Diego, CA, UNITED STATES  
Strem, Brian M., San Diego, CA, UNITED STATES  
Daniels, Eric, Santa Clarita, CA, UNITED STATES  
Wulur, Isabella, West Hills, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005008626	A1	20050113
APPLICATION INFO.:	US 2004-783957	A1	20040220 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-316127, filed on 9 Dec 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338856P	20011207 (60)
	US 2003-449279P	20030220 (60)
	US 2003-462911P	20030415 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Kenton R. Mullins, Stout, Uxa, Buyan & Mullins, LLP,  
Suite 300, 4 Venture, Irvine, CA, 92618  
NUMBER OF CLAIMS: 82  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 9 Drawing Page(s)  
LINE COUNT: 2850

AB Cells present in processed lipoaspirate tissue are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed **directly** into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.

L9 ANSWER 14 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2005:5321 USPATFULL  
TITLE: Cardiac disease treatment and device  
INVENTOR(S): Cox, James, Hamel, MN, UNITED STATES  
Girard, Michael J., Lino Lakes, MN, UNITED STATES  
Palme, Donald F., II, Princeton, MN, UNITED STATES  
Rohrbaugh, Donald G., Minnetonka, MN, UNITED STATES  
Sabbah, Hani N., Waterford, MI, UNITED STATES  
Shapland, J. Edward, Vadnais Heights, MN, UNITED STATES  
Walsh, Robert G., Lakeville, MN, UNITED STATES  
PATENT ASSIGNEE(S): Acorn Cardiovascular, Inc., St. Paul, MN (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005004428	A1	20050106
APPLICATION INFO.:	US 2004-839724	A1	20040504 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-591875, filed on 12 Jun 2000, GRANTED, Pat. No. US 6730016		

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Attention of Anna M. Nelson, MERCHANT & GOULD P.C.,  
P.O. Box 2903, Minneapolis, MN, 55402-0903

NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 9 Drawing Page(s)  
LINE COUNT: 1719

AB A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A-V groove, the device including a jacket adapted to be secured to the heart, and a non-adherent material in association with the jacket. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.

L9 ANSWER 15 OF 54 USPATFULL on STN  
 ACCESSION NUMBER: 2005:3907 USPATFULL  
 TITLE: Injectable cross-linked polymeric preparations and uses thereof  
 INVENTOR(S): Cohen, Smadar, Beer-Sheva, ISRAEL  
 Leor, Jonathan, Gane Tikva, ISRAEL  
 PATENT ASSIGNEE(S): BEN-GURION UNIVERSITY OF THE NEGEV, Beer-Sheva, ISRAEL  
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005003010	A1	20050106
APPLICATION INFO.:	US 2004-840008	A1	20040505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2003-155774	20030505
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	1866	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB A composition for promoting repair of damaged tissues, being a cross-linked alginate solution, which can be maintained in liquid form indefinitely (under constant conditions) and only gels in vivo. This cross-linked alginate solution is an ideal material to be used for tissue repair. Injection of said material into cardiac tissue post-myocardial infarct induced tissue **regeneration**. The invention provides such injectable solution, as well as compositions and method of preparation thereof. The invention also provides various methods and uses of the cross-linked alginate solution, for cardiac tissue **regeneration**, induction of neo-vascularization, enhancing SDF-1 expression and guiding stem cell chemotaxis, among others. A kit for tissue repair is also provided.

L9 ANSWER 16 OF 54 USPATFULL on STN  
 ACCESSION NUMBER: 2005:3813 USPATFULL  
 TITLE: Enhancement of **angiogenesis** to grafts using cells engineered to produce growth factors  
 INVENTOR(S): Atala, Anthony, Winston Salem, NC, UNITED STATES  
 Stoker, Shay, Greensboro, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005002915	A1	20050106
APPLICATION INFO.:	US 2004-766642	A1	20040128 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-443129P	20030128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NUTTER MCCLENNEN & FISH LLP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02210-2604	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	4126	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention provides methods and compositions of engineered cells for use in the continuous or transient delivery of growth factors and **angiogenesis** modulating agents, such as vascular endothelial growth factor (VEGF), in conjunction with constructs for replacing or augmenting organ functions. In one aspect of the invention, the genetically engineered cells can be immature cells that are capable of differentiating and assimilating into the target region. The methods of the present invention can be used to enhance vascularization locally at a target site in need of repair, growth, or **implantation** through the incorporation of autologous cells which have been genetically engineered to secrete a growth factor or **angiogenesis** modulating agent.

L9 ANSWER 17 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:326850 USPATFULL  
TITLE: Mesenchymal stem cells and methods of use thereof  
INVENTOR(S): Dzau, Victor J., Newton, MA, UNITED STATES  
Mangi, Abeel, Brookline, MA, UNITED STATES  
Ip, James Edmund, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004258669	A1	20041223
APPLICATION INFO.:	US 2003-701789	A1	20031105 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-423805P	20021105 (60)
	US 2003-493874P	20030808 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ingrid A. Beattie, Ph.D., J.D., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	90	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	2348	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of **regenerating** a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant. The mesenchymal stem cell is an adult cell obtained from an adult **bone marrow**.

L9 ANSWER 18 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:273265 USPATFULL  
TITLE: Methods and compositions to treat **myocardial** conditions  
INVENTOR(S): Michal, Eugene T., San Francisco, CA, UNITED STATES  
Mandrusov, Evgenia, Campbell, CA, UNITED STATES  
Claude, Charles D., Santa Clara, CA, UNITED STATES  
Ding, Ni, San Jose, CA, UNITED STATES  
Simhambhatla, Murthy, San Jose, CA, UNITED STATES  
Hossainy, Syed Faiyaz Ahmed, Fremont, CA, UNITED STATES  
Sridharan, Srinivasan, Morgan Hill, CA, UNITED STATES  
Consigny, Paul, San Jose, CA, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2004213756 A1 20041028  
APPLICATION INFO.: US 2003-414767 A1 20030415 (10)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BLAKELY SOKOLOFF TAYLOR & ZAFMAN, 12400 WILSHIRE  
BOULEVARD, SEVENTH FLOOR, LOS ANGELES, CA, 90025-1030  
NUMBER OF CLAIMS: 82  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Page(s)  
LINE COUNT: 2862  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, devices, kits and compositions to treat a **myocardial** infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

L9 ANSWER 19 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:267308 USPATFULL

TITLE: Methods and compositions to treat **myocardial** conditions

INVENTOR(S): Michal, Eugene T., San Francisco, CA, UNITED STATES  
Mandrusov, Evgenia, Campbell, CA, UNITED STATES  
Claude, Charles D., Santa Clara, CA, UNITED STATES  
Ding, Ni, San Jose, CA, UNITED STATES  
Simhambhatla, Murthy, San Jose, CA, UNITED STATES  
Ahmed Hossainy, Syed Faiyez, Fremont, CA, UNITED STATES  
Sridharan, Srinivasan, Morgan Hill, CA, UNITED STATES  
Consigny, Paul, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004208845	A1	20041021
APPLICATION INFO.:	US 2003-414602	A1	20030415 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BLAKELY SOKOLOFF TAYLOR & ZAFMAN, 12400 WILSHIRE BOULEVARD, SEVENTH FLOOR, LOS ANGELES, CA, 90025-1030		
NUMBER OF CLAIMS:	101		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	2925		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, devices, kits and compositions to treat a **myocardial** infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to

pro-fibroblastic and angiogenic agents.

L9 ANSWER 20 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:240608 USPATFULL  
TITLE: Systems and methods for treating **ischemia**  
INVENTOR(S): Cafferata, Robert L., Belmont, MA, UNITED STATES  
PATENT ASSIGNEE(S): C. R. Bard, Inc., Murray Hill, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004186423	A1	20040923
APPLICATION INFO.:	US 2004-767551	A1	20040129 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-159834, filed on 24 Sep 1998, GRANTED, Pat. No. US 6689121		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KIRKPATRICK & LOCKHART LLP, 75 STATE STREET, BOSTON, MA, 02109-1808		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	986		

AB A system and method for **implanting** pellets into **myocardial** tissue for treatment of coronary artery restenosis, **ischemic** heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

L9 ANSWER 21 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:232972 USPATFULL  
TITLE: Cardiac transplantation of stem cells for the treatment of heart failure  
INVENTOR(S): Sabbah, Hani, Detroit, MI, UNITED STATES  
Sharov, Victor G., Detroit, MI, UNITED STATES  
Ishigai, Yukata, Detroit, MI, UNITED STATES  
Maltsev, Victor, Detroit, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004180043	A1	20040916
APPLICATION INFO.:	US 2003-700032	A1	20031103 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US29595, filed on 18 Sep 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323351P	20010919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Amy E. Rinaldo, KOHN & ASSOCIATES, PLLC, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI, 48334	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	928	

AB A method of treating heart failure and improving cardiac function by administering stem cell products to a heart in need of treatment, whereby the stem cell products improve cardiac muscle function thereby treating heart failure and improving cardiac function. A method of enriching or **regenerating** damaged **myocardium** by administering stem cell products to damaged **myocardium**. Stem



cell products for use in treating heart failure are also provided. A composition for enriching and **regenerating** damaged **myocardium**, the composition having stem cell products in a pharmaceutically acceptable carrier.

L9 ANSWER 22 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:177802 USPATFULL

TITLE: Methods and compositions for the repair and/or **regeneration** of damaged **myocardium**

INVENTOR(S): Anversa, Piero, New York, NY, UNITED STATES

Orlic, Donald, Bethesda, MD, UNITED STATES

PATENT ASSIGNEE(S): The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004136966	A1	20040715
APPLICATION INFO.:	US 2003-444553	A1	20030522 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-430100, filed on 5 May 2003, PENDING Continuation of Ser. No. US 2001-919979, filed on 31 Jul 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221902P	20000731 (60)
	US 2000-258564P	20001229 (60)
	US 2001-258805P	20010102 (60)
	US 2001-295807P	20010606 (60)
	US 2001-295806P	20010606 (60)
	US 2001-295805P	20010606 (60)
	US 2001-295804P	20010606 (60)
	US 2001-295803P	20010606 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 1875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and kits for repairing damaged **myocardium** and/or **myocardial** cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.

L9 ANSWER 23 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:113650 USPATFULL

TITLE: Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

INVENTOR(S): Liao, Gene, Darnestown, MD, UNITED STATES

Stefansson, Steingrímur, Gaithersburg, MD, UNITED STATES

Su, Joseph, Germantown, MD, UNITED STATES

PATENT ASSIGNEE(S): Novartis AG (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004086487	A1	20040506
APPLICATION INFO.:	US 2003-619344	A1	20030714 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-970516, filed on 4 Oct 2001, GRANTED, Pat. No. US 6610534		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-238230P	20001005 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1466	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.

L9 ANSWER 24 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:109752 USPATFULL  
 TITLE: Cardiac disease treatment and device  
 INVENTOR(S): Cox, James, Hamel, MN, United States  
 Girard, Michael J., Lino Lakes, MN, United States  
 Palme, II, Donald F., Princeton, MN, United States  
 Rohrbaugh, Donald G., Minnetonka, MN, United States  
 Sabbah, Hani N., Waterford, MI, United States  
 Shapland, II, J. Edward, Vadnais Heights, MN, United States  
 Walsh, Robert G., Lakeville, MN, United States  
 PATENT ASSIGNEE(S): Acorn Cardiovascular, Inc., St. Paul, MN, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6730016	B1	20040504
APPLICATION INFO.:	US 2000-591875		20000612 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Hindenburg, Max F.		
ASSISTANT EXAMINER:	Szmal, Brian		
LEGAL REPRESENTATIVE:	Merchant & Gould P.C.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	1875		

AB A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A-V groove, the device including a jacket adapted to be secured to the heart, and a non-adherent material in association with the jacket. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including

surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.

L9 ANSWER 25 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:100758 USPATFULL  
TITLE: Methods and compositions for the repair and/or  
**regeneration** of damaged **myocardium**  
INVENTOR(S): Anversa, Piero, New York, NY, UNITED STATES  
Orlic, Donald, Bethesda, MD, UNITED STATES  
PATENT ASSIGNEE(S): The Government of the United States of America as  
represented by the Department of Health and (U.S.  
corporation)  
Human Services (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004076619	A1	20040422
APPLICATION INFO.:	US 2003-430100	A1	20030505 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-919979, filed on 31 Jul 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221902P	20000731 (60)
	US 2000-258564P	20001229 (60)
	US 2001-258805P	20010102 (60)
	US 2001-295807P	20010606 (60)
	US 2001-295806P	20010606 (60)
	US 2001-295805P	20010606 (60)
	US 2001-295804P	20010606 (60)
	US 2001-295803P	20010606 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE  
#1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988

NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 29 Drawing Page(s)  
LINE COUNT: 1874

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and kits for repairing damaged **myocardium**  
and/or **myocardial** cells including the administration of stem  
cells, such as adult stem cells, optionally with cytokines are disclosed  
and claimed.

L9 ANSWER 26 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:33779 USPATFULL  
TITLE: Systems and methods for treating **ischemia**  
INVENTOR(S): Cafferata, Robert L., Belmont, MA, United States  
PATENT ASSIGNEE(S): C. R. Bard, Inc., Murray Hill, NJ, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689121	B1	20040210
APPLICATION INFO.:	US 1998-159834		19980924 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lo, Weilun		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 4 Drawing Page(s)  
LINE COUNT: 1155

AB A system and method for **implanting** pellets into **myocardial** tissue for treatment of coronary artery restenosis, **ischemic** heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

L9 ANSWER 27 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:31195 USPATFULL  
TITLE: Modified transferrin fusion proteins  
INVENTOR(S): Prior, Christopher P., Philadelphia, PA, UNITED STATES  
PATENT ASSIGNEE(S): BioRexis Pharmaceutical Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023334	A1	20040205
APPLICATION INFO.:	US 2002-231494	A1	20020830 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	15780	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

L9 ANSWER 28 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2004:4396 USPATFULL  
TITLE: Muscle cells and their use in cardiac repair  
INVENTOR(S): Edge, Albert, Cambridge, MA, United States  
PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673604	B1	20040106
APPLICATION INFO.:	US 2000-624885		20000724 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-145849P	19990723 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Chan, Christina	
ASSISTANT EXAMINER:	VanderVegt, F. Pierre	
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart, Jarrell, Brenda Herschbach	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 7 Drawing Page(s)	

LINE COUNT: 2127

AB Muscle cells and methods for using the muscle cells are provided. In one embodiment, the invention provides transplantable skeletal muscle cell compositions and their methods of use. In one embodiment, the muscle cells can be transplanted into patients having disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a subject by administering the skeletal myoblasts to the subject. The muscle cells can be autologous, allogeneic, or xenogeneic to the recipient.

L9 ANSWER 29 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:330220 USPATFULL

TITLE: Cellular transplantation for heart **regeneration**

INVENTOR(S): Law, Peter K., Germantown, TN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232431	A1	20031218
APPLICATION INFO.:	US 2003-403520	A1	20030401 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-368563P	20020401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1021	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. **Angiogenesis** factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated **catheter** delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.

L9 ANSWER 30 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:318656 USPATFULL

TITLE: Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof

INVENTOR(S): Barber, Lauren E., Higganum, CT, UNITED STATES  
Cacace, Angela, Clinton, CT, UNITED STATES  
Feder, John N., Belle Mead, NJ, UNITED STATES  
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES  
Bol, David K., Gaithersburg, MD, UNITED STATES  
Ramanathan, Chandra, Wallingford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224400	A1	20031204
APPLICATION INFO.:	US 2003-369405	A1	20030214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-991225, filed		

on 16 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249613P	20001117 (60)
	US 2000-257611P	20001221 (60)
	US 2001-305818P	20010716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15695	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders, ovarian cancer, and diseases and disorders related to aberrant NFkB modulation. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L9 ANSWER 31 OF 54 USPTAFULL on STN

ACCESSION NUMBER: 2003:238706 USPTAFULL  
TITLE: Human tumor necrosis factor delta and epsilon  
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Gentz, Reiner, Belo Horizonte-Mg, BRAZIL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166864	A1	20030904
APPLICATION INFO.:	US 2002-268951	A1	20021011 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-879919, filed on 14 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170 Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170 Continuation-in-part of Ser. No. US 2002-82260, filed on 26 Feb 2002, GRANTED, Pat. No. US 6506882 Division of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-328401P	20011012 (60)
	US 2000-211537P	20000615 (60)
	US 2000-241952P	20001023 (60)
	US 2000-254875P	20001213 (60)
	US 2001-277978P	20010323 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 1996-16812P	19960314 (60)
	US 1996-16812P	19960314 (60)

US 1996-16812P 19960314 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 50  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 11 Drawing Page(s)  
LINE COUNT: 14873  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to human TNF delta and TNF epsilon polypeptides,  
polynucleotides encoding the polypeptides, methods for producing the  
polypeptides, in particular by expressing the polynucleotides, and  
agonists and antagonists of the polypeptides. The invention further  
relates to methods for utilizing such polynucleotides, polypeptides,  
agonists and antagonists for applications, which relate, in part, to  
research, diagnostic and clinical arts.

L9 ANSWER 32 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 2003:238383 USPATFULL  
TITLE: 83 human secreted proteins  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Feng, Ping, Germantown, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Kyaw, Hla, Frederick, MD, UNITED STATES  
Li, Yi, Sunnyvale, CA, UNITED STATES  
Zeng, Zhizhen, Lansdale, PA, UNITED STATES  
Carter, Kenneth C., North Potomac, MD, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Wei, Ying-Fei, Berkeley, CA, UNITED STATES  
Fan, Ping, Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166541	A1	20030904
APPLICATION INFO.:	US 2002-160162	A1	20020604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-236557, filed on 26 Jan 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US15949, filed on 29 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295558P	20010605 (60)
	US 1997-54209P	19970730 (60)
	US 1997-54211P	19970730 (60)
	US 1997-54212P	19970730 (60)
	US 1997-54213P	19970730 (60)
	US 1997-54214P	19970730 (60)
	US 1997-54215P	19970730 (60)
	US 1997-54217P	19970730 (60)
	US 1997-54218P	19970730 (60)
	US 1997-54234P	19970730 (60)
	US 1997-54236P	19970730 (60)
	US 1997-55968P	19970818 (60)
	US 1997-55969P	19970818 (60)
	US 1997-55972P	19970818 (60)
	US 1997-56534P	19970819 (60)
	US 1997-56543P	19970819 (60)

US 1997-56554P	19970819 (60)
US 1997-56561P	19970819 (60)
US 1997-56727P	19970819 (60)
US 1997-56729P	19970819 (60)
US 1997-56730P	19970819 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Page(s)  
 LINE COUNT: 24088

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L9 ANSWER 33 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:219773 USPATFULL

TITLE: Novel human G-protein coupled receptor, HGPRBMY11,  
 expressed highly in heart and variants thereof

INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES  
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES  
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
 Cacace, Angela M., Clinton, CT, UNITED STATES  
 Barber, Lauren E., Griswood, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153063	A1	20030814
APPLICATION INFO.:	US 2001-991225	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-249613P	20001117 (60)
	US 2000-257611P	20001221 (60)
	US 2001-305818P	20010716 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT  
 DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS: 41  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 19 Drawing Page(s)  
 LINE COUNT: 16070

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present



invention.

L9 ANSWER 34 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:173232 USPATFULL  
TITLE: B7-like polynucleotides, polypeptides, and antibodies  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Chen, Lieping, Rochester, MN, UNITED STATES  
Baker, Kevin P., Darnestown, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119076	A1	20030626
APPLICATION INFO.:	US 2002-141953	A1	20020510 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-790622, filed on 23 Feb 2001, PENDING Continuation-in-part of Ser. No. WO 2000-US23792, filed on 30 Aug 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152317P	19990903 (60)
	US 2000-200346P	20000428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	12418	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention relates to novel human B7-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human B7-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human B7-like polypeptides.

L9 ANSWER 35 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:165871 USPATFULL  
TITLE: Human single nucleotide polymorphisms  
INVENTOR(S): Tsuchihashi, Zenta, Pennington, NJ, UNITED STATES  
Hui, Lester, Fairfax, VA, UNITED STATES  
Zerba, Kim, New Hope, PA, UNITED STATES  
Ma-Edmonds, Manling, Lawrenceville, NJ, UNITED STATES  
Perrone, Mark, Princeton, NJ, UNITED STATES  
Swanson, Brian, Yardley, PA, UNITED STATES  
Powell, James, Lumberville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113726	A1	20030619
APPLICATION INFO.:	US 2001-5956	A1	20011203 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251015P	20001204 (60)
	US 2001-263678P	20010123 (60)
	US 2001-273037P	20010302 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT  
DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000  
NUMBER OF CLAIMS: 50  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 108 Drawing Page(s)  
LINE COUNT: 21863  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides polynucleotides and polypeptides corresponding to novel gene sequences associated with the incidence of cardiovascular disorders. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these genes which comprise at least one polymorphic site per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic site are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, paternity testing, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly cardiovascular diseases related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L9 ANSWER 36 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 2003:165447 USPATFULL  
TITLE: Muscle cells and their use in cardiac repair  
INVENTOR(S): Edge, Albert, Cambridge, MA, UNITED STATES  
Dinsmore, Jonathan, Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113301	A1	20030619
APPLICATION INFO.:	US 2002-105035	A1	20020321 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-624885, filed on 24 Jul 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-145849P	19990723 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Monica R. Gerber, M.D., Ph.D., Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	3064	
AB	Muscle cells and methods for using the muscle cells are provided. In one embodiment, the invention provides transplantable skeletal muscle cell compositions and their methods of use. In one embodiment, the muscle cells can be transplanted into patients having disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a subject by administering the skeletal myoblasts to the subject. The muscle cells can be autologous, allogeneic, or xenogeneic to the recipient.	

L9 ANSWER 37 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 2003:153350 USPATFULL  
TITLE: Use of vegf and homologues to treat neuron disorders

INVENTOR(S): Carmeliet, Peter, Landen, BELGIUM  
Collen, Desire, Winksele, BELGIUM  
Oosthuyse, Bert, Ooigem, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105018	A1	20030605
APPLICATION INFO.:	US 2002-257423	A1	20021010 (10)
	WO 2001-EP4293		20010412

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-201325	20000412
	EP 2000-203382	20000929
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Elie H Gendloff, Amster Rothstein & Ebenstein, 90 Park Avenue, New York, NY, 10016	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1562	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In (particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGF.sup.m/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)--a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF.sub.165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF.sub.165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.

L9 ANSWER 38 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 2003:107065 USPATFULL  
TITLE: Medical device for delivering patches  
INVENTOR(S): Naimark, Wendy, Cambridge, MA, UNITED STATES  
Palasis, Maria, Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073979	A1	20030417
	US 6893431	B2	20050517
APPLICATION INFO.:	US 2001-977758	A1	20011015 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	1466		

AB The present invention relates to a medical device and method for treating the body tissue of a patient. The present invention is also **directed** to a method of making the medical device and a method of using the medical device. More particularly, the invention relates to a medical device which is inserted into the body for delivery of therapeutic patches to the surface of a body lumen, organ or cavity. Specifically, the medical device has an umbrella-like or a basket-like expandable assembly; and a therapeutic patch. The expandable assembly is capable of changing from a retracted position to an expanded position. The expandable assembly can be self-expanding or non-self-expanding. In one embodiment, the medical device comprises an elongated member; an umbrella-like expandable assembly which has a plurality of wire elements; and a therapeutic patch. The therapeutic patch comprises a sheet having two opposing surfaces wherein one of the surface comprises an adhesive material and at least one biologically active material. The other opposing surface is disposed onto the plurality of wire elements of the umbrella-like expandable assembly. In another embodiment, the medical device comprises an elongated member, a basket-like expandable assembly having a plurality of wire elements; and a therapeutic patch. The therapeutic patch is disposed onto the plurality of wire elements of the basket-like expandable assembly.

L9 ANSWER 39 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:79048 USPATFULL

TITLE: Methods and compositions for the repair and/or **regeneration** of damaged **myocardium**

INVENTOR(S): Anversa, Piero, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003054973	A1	20030320
APPLICATION INFO.:	US 2002-162796	A1	20020605 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-919732, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295807P	20010606 (60)
	US 2001-295806P	20010606 (60)
	US 2001-295805P	20010606 (60)
	US 2001-295804P	20010606 (60)
	US 2001-295803P	20010606 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151

NUMBER OF CLAIMS: 80

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 95 Drawing Page(s)

LINE COUNT: 3875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and kits for repairing damaged **myocardium** and/or **myocardial** cells including the administration cytokines are disclosed and claimed.

L9 ANSWER 40 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:64783 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044904	A1	20030306
APPLICATION INFO.:	US 2002-73865	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764893, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)

US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)

US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 26421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L9 ANSWER 41 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:64772 USPATFULL

TITLE: Nectin polypeptides, polynucleotides, methods of making and use thereof

INVENTOR(S): Baum, Peter R., Seattle, WA, UNITED STATES  
Fanslow, William C., III, Normandy Park, WA, UNITED STATES  
Lofton, Timothy E., Marysville, WA, UNITED STATES  
Sorensen, Eric A., Lynnwood, WA, UNITED STATES  
Youakim, Adel, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044893	A1	20030306
APPLICATION INFO.:	US 2001-972268	A1	20011005 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-238557P	20001005 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: IMMUNEX CORPORATION, LAW DEPARTMENT, 51 UNIVERSITY STREET, SEATTLE, WA, 98101

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 7002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and **angiogenesis**, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function, and to identify agents that alter nectin polypeptide activities.

L9 ANSWER 42 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:30223 USPATFULL

TITLE: Novel **fibroblast** growth factors and therapeutic and diagnostic uses therefor

INVENTOR(S): Khodadoust, Mehran Mohamad, Chestnut Hill, MA, UNITED STATES

PATENT ASSIGNEE(S): Millenium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022170	A1	20030130
APPLICATION INFO.:	US 2001-820596	A1	20010329 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-36594, filed on 6 Mar 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	5307		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery of novel genes encoding a **fibroblast** growth factor, MFGF. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.

L9 ANSWER 43 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2003:11120 USPATFULL

TITLE: Stimulation of vascularization with VEGF-B

INVENTOR(S): Eriksson, Ulf, Stockholm, SWEDEN

Li, Xuri, Stockholm, SWEDEN

Carmeliet, Peter, Zwijnaarde, BELGIUM

Collen, Desire, Zwijnaarde, BELGIUM

PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, New York, NY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008824	A1	20030109
APPLICATION INFO.:	US 2002-175153	A1	20020620 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-299192P	20010620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O.	



BOX 14300, WASHINGTON, DC, 20044-4300

NUMBER OF CLAIMS: 25  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 921  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. **angiogenesis** and/or arteriogenesis, particularly in **ischemic** mammals, are disclosed.

L9 ANSWER 44 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:344413 USPATFULL  
TITLE: B7-like polynucleotides, polypeptides, and antibodies  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Chen, Lieping, Rochester, MN, UNITED STATES  
Baker, Kevin P., Darnestown, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198143	A1	20021226
APPLICATION INFO.:	US 2001-790622	A1	20010223 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US23792, filed on 30 Aug 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152317P	19990903 (60)
	US 2000-200346P	20000428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	12424	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human B7-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human B7-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human B7-like polypeptides.

L9 ANSWER 45 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:307545 USPATFULL  
TITLE: Localized **myocardial** injection method for treating **ischemic myocardium**  
INVENTOR(S): Palasis, Maria, Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002172663	A1	20021121
APPLICATION INFO.:	US 2002-57409	A1	20020123 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-263468P	20010123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Hale and Dorr LLP, 300 Park Avenue, New York, NY, 10022  
NUMBER OF CLAIMS: 54  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Page(s)  
LINE COUNT: 786  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method of treating **ischemic** or diseased **myocardium** by injecting a therapeutic agent, such as a gene, protein, cell or drug, into normal **myocardium**, preferably adjacent to an **ischemic** zone in the heart of a subject. The method is useful for inducing **angiogenesis** and collateral blood vessel formation to improve cardiac function in subjects with **ischemic** heart disease. The method can also be used to promote tissue **regeneration** in such subjects.

L9 ANSWER 46 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:294649 USPATFULL  
TITLE: Immune system-related polynucleotides, polypeptides, and antibodies

INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES  
Hilbert, David, Bethesda, MD, UNITED STATES  
Kenny, Joseph J., Damascus, MD, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Choi, Gil H., Rockville, MD, UNITED STATES  
Soppet, Daniel R., Centreville, VA, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Gruber, Joachim R., Dallas, TX, UNITED STATES  
Endress, Gregory A., Florence, MA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164692	A1	20021107
APPLICATION INFO.:	US 2001-949842	A1	20010912 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US7260, filed on 7 Mar 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-187873P	20000308 (60)
	US 2000-224367P	20000811 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 13952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human immune system-related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human immune system-related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human immune system-related polypeptides.

L9 ANSWER 47 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:280103 USPATFULL  
TITLE: Calcium channel polynucleotides, polypeptides, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES

PATENT ASSIGNEE(S): Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Human Genome Sciences, Inc., Rockville, MD (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155539	A1	20021024
APPLICATION INFO.:	US 2002-50786	A1	20020118 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-774028, filed on 31 Jan 2001, PENDING Continuation-in-part of Ser. No. WO 2000-US20392, filed on 27 Jul 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-145958P	19990728 (60)
	US 1999-149446P	19990818 (60)
	US 2000-189064P	20000314 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 11310

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human calcium channel  
polypeptides and isolated nucleic acids containing the coding regions of  
the genes encoding such polypeptides. Also provided are vectors, host  
cells, antibodies, and recombinant methods for producing human calcium  
channel polypeptides. The invention further relates to diagnostic and  
therapeutic methods useful for diagnosing and treating disorders related  
to these novel human calcium channel polypeptides.

L9 ANSWER 48 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:198680 USPATFULL  
TITLE: Extracellular matrix polynucleotides, polypeptides, and  
antibodies

INVENTOR(S): Fiscella, Michele, Bethesda, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106780	A1	20020808
APPLICATION INFO.:	US 2001-978249	A1	20011017 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US11643, filed on 11 Apr 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-198123P	20000418 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 13488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human extracellular matrix  
polypeptides and isolated nucleic acids containing the coding regions of  
the genes encoding such polypeptides. Also provided are vectors, host

cells, antibodies, and recombinant methods for producing human extracellular matrix polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human extracellular matrix polypeptides.

L9 ANSWER 49 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:186108 USPATFULL

TITLE: Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

INVENTOR(S): Liao, Gene, Darnestown, MD, UNITED STATES  
Stefansson, Steingrímur, Gaithersburg, MD, UNITED STATES  
Su, Joseph, Germantown, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099029	A1	20020725
	US 6610534	B2	20030826
APPLICATION INFO.:	US 2001-970516	A1	20011004 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-238230P	20001005 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1473	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.

L9 ANSWER 50 OF 54 USPATFULL on STN

ACCESSION NUMBER: 2002:185259 USPATFULL

TITLE: Methods and compositions for the repair and/or **regeneration** of damaged **myocardium**

INVENTOR(S): Anversa, Piero, New York, NY, UNITED STATES  
Orlic, Donald, Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098167	A1	20020725
APPLICATION INFO.:	US 2001-919979	A1	20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221902P	20000731 (60)
	US 2000-258564P	20001229 (60)
	US 2001-258805P	20010102 (60)
	US 2001-295807P	20010606 (60)

US 2001-295806P 20010606 (60)  
 US 2001-295805P 20010606 (60)  
 US 2001-295804P 20010606 (60)  
 US 2001-295803P 20010606 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: THOMAS J. KOWALSKI, FROMMER LAWRENCE & HAUG LLP, 745  
 Fifth Avenue, New York, NY, 10151  
 NUMBER OF CLAIMS: 20  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 29 Drawing Page(s)  
 LINE COUNT: 1843  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and kits for repairing damaged **myocardium**  
 and/or **myocardial** cells including the administration of stem  
 cells, such as adult stem cells, optionally with cytokines are disclosed  
 and claimed.

L9 ANSWER 51 OF 54 USPATFULL on STN  
 ACCESSION NUMBER: 2002:164712 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086330	A1	20020704
APPLICATION INFO.:	US 2001-764893	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)

US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 25862  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

L9 ANSWER 52 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 2002:119604 USPATFULL  
TITLE: Methods and compositions for the repair and/or  
**regeneration** of damaged **myocardium**  
INVENTOR(S): Anversa, Piero, New York, NY, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2002061587 A1 20020523  
APPLICATION INFO.: US 2001-919732 A1 20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221902P	20000731 (60)
	US 2000-258564P	20001229 (60)
	US 2001-258805P	20010102 (60)
	US 2001-295807P	20010606 (60)
	US 2001-295806P	20010606 (60)
	US 2001-295805P	20010606 (60)
	US 2001-295804P	20010606 (60)
	US 2001-295803P	20010606 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: THOMAS J. KOWALSKI, FROMMER LAWRENCE & HAUG LLP, 745  
Fifth Avenue, New York, NY, 10151

NUMBER OF CLAIMS: 153  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 29 Drawing Page(s)  
LINE COUNT: 2582

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compositions, and kits for repairing damaged **myocardium**  
and/or **myocardial** cells including the administration of stem  
cells, such as adult stem cells, optionally with cytokines are disclosed  
and claimed.

L9 ANSWER 53 OF 54 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2004:35555 EPFULL  
UPDATE DATE PUBLICAT.: 20050831  
DATA UPDATE DATE: 20050831  
DATA UPDATE WEEK: 200535  
TITLE (ENGLISH): Systems and methods for treating **ischemia**  
TITLE (FRENCH): Systemes and methodes de traitement de l'  
**ischemie**  
TITLE (GERMAN): Vorrichtung und Verfahren zur Behandlung von Ischaemie  
INVENTOR(S): Cafferata, Robert L., 55 Warwick Road, Belmont  
Massachusetts 02178, US  
PATENT APPLICANT(S): C.R. Bard Inc., 730 Central Avenue, Murray Hill, NJ  
07974, US  
PATENT APPL. NUMBER: 2255750  
AGENT: HOFFMANN EITLE, Patent- und Rechtsanwaelte  
Arabellastrasse 4, 81925 Muenchen, DE  
AGENT NUMBER: 101511  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
LANGUAGE OF PROCEDURE: English  
LANGUAGE OF TITLE: German; English; French  
DOCUMENT TYPE: Patent  
PATENT INFO TYPE: EPA1 Application published with search report  
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES:	EP 1484081	A1	20041208
APPLICATION INFO.:	DE ES FR GB IT		
RELATED DOC. INFO.:	EP 2004-21459	A	19990924
	EP 1999-949916		19990924
	Application		EP 1115452 Parent
PRIORITY INFO.:	US 1998-159834	A	19980924

ABEN

An **implant** (22) for **myocardial** tissue for treatment

of coronary artery restenosis, **ischemic** heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

(image, 0.1, abstract drawing)

L9 ANSWER 54 OF 54 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:78193 EPFULL  
 UPDATE DATE PUBLICAT.: 20051116  
 DATA UPDATE DATE: 20051116  
 DATA UPDATE WEEK: 200546  
 TITLE (ENGLISH): SYSTEM FOR TREATING **ISCHEMIA**  
 TITLE (FRENCH): SYSTEMES DE TRAITEMENT DE L'**ISCHEMIE**  
 TITLE (GERMAN): VORRICHTUNG ZUR BEHANDLUNG VON ISCHAEMIE  
 INVENTOR(S): CAFFERATA, Robert, L., 55 Warwick Road, Belmont, MA 02178, US  
 PATENT APPLICANT(S): C.R. Bard Inc., 730 Central Avenue, Murray Hill, NJ 07974, US  
 PATENT APPL. NUMBER: 2255750  
 AGENT: HOFFMANN EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925 Muenchen, DE  
 AGENT NUMBER: 101511  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 LANGUAGE OF PROCEDURE: English  
 LANGUAGE OF TITLE: German; English; French  
 DOCUMENT TYPE: Patent  
 PATENT INFO TYPE: EPB1 Granted patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE

EP 1115452	B1	20041124
------------	----	----------

WO 2000016848		20000330
---------------	--	----------

DESIGNATED STATES: DE ES FR GB IT

APPLICATION INFO.: EP 1999-949916 A 19990924

WO 1999-US22392 A 19990924

RELATED DOC. INFO.: EP 2004-21459 20040909

EP 1484081

Divisional Application

PRIORITY INFO.: US 1998-159834 A 19980924

CITED PATENT LIT.: EP 853921 A

WO 9427612 A

WO 9533511 A

WO 9620698 A

WO 9745105 A

US 5180366 A